Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)
| Autor: | Eduard Molins, Dave Singh, Eric D. Bateman, Anthony D'Urzo, Kenneth R. Chapman, Esther Garcia Gil, Anne Leselbaum |
|---|---|
| Přispěvatelé: | Division of Pulmonology, Faculty of Health Sciences |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine medicine.medical_specialty Time Factors Exacerbation Population Placebo Pulmonary Disease Chronic Obstructive Aclidinium bromide Double-Blind Method Internal medicine Formoterol Fumarate Aclidinium bromide/formoterol fumarate Administration Inhalation medicine media_common.cataloged_instance Humans European union education Adrenergic beta-2 Receptor Agonists media_common Aged education.field_of_study COPD business.industry Anticholesteremic Agents Research Chronic obstructive pulmonary disease Fixed-dose combination Middle Aged medicine.disease 3. Good health respiratory tract diseases Drug Combinations Anesthesia Symptoms Disease Progression Female Formoterol business medicine.drug Tropanes |
| Zdroj: | Respiratory Research |
| DOI: | 10.1186/s12931-015-0250-2 |
| Popis: | Background The combination of aclidinium bromide, a long-acting anticholinergic, and formoterol fumarate, a long-acting beta2-agonist (400/12 μg twice daily) achieves improvements in lung function greater than either monotherapy in patients with chronic obstructive pulmonary disease (COPD), and is approved in the European Union as a maintenance treatment. The effect of this combination on symptoms of COPD and exacerbations is less well established. We examined these outcomes in a pre-specified analysis of pooled data from two 24-week, double-blind, parallel-group, active- and placebo-controlled, multicentre, randomised Phase III studies (ACLIFORM and AUGMENT). Methods Patients ≥40 years with moderate to severe COPD (post-bronchodilator forced expiratory volume in 1 s [FEV1]/forced vital capacity |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|